

*Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 20 April 2015 (the “Prospectus”) issued by Shanghai Haohai Biological Technology Co., Ltd. (the “Company”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company, the Hong Kong Public Offer and the International Placing described below before deciding whether or not to invest in the H Shares thereby offered.*

*This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States.*



**Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People’s Republic of China with limited liability)*

**(Stock Code: 6826)**

**END OF STABILIZATION PERIOD,  
STABILIZING ACTIONS AND PARTIAL  
EXERCISE OF OVER-ALLOTMENT OPTION**

The Company announces that the stabilization period in connection with the Global Offering ended on 23 May 2015, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offer.

The Company was informed by UBS AG Hong Kong Branch, the Stabilizing Manager, that the stabilizing actions undertaken by UBS AG Hong Kong Branch, its affiliates or any person acting for it during the stabilization period were:

- (i) over-allocation of an aggregate of 6,000,000 additional H Shares in the International Placing, representing in aggregate of 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (ii) successive purchases of an aggregate of 5,954,700 H Shares in the price range of HK\$53.50 to HK\$59.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period. The last purchase made by the Stabilizing Manager on the market during the course of the stabilization period was on 22 May 2015 at the price of HK\$59.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%); and
- (iii) partial exercise of the Over-allotment Option by the Sole Global Coordinator, on behalf of the International Underwriters, on 23 May 2015 in respect of an aggregate of 45,300 H Shares, representing in aggregate of 0.11% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per H Share.

## **PARTIAL EXERCISE OF OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Sole Global Coordinator (on behalf of the International Underwriters) on 23 May 2015 in respect of an aggregate of 45,300 additional H Shares (the “**Over-allotment Shares**”), representing in aggregate of 0.11% of the Offer Shares initially available under the Global Offering, to partially cover over-allocations in the International Placing.

The Over-allotment Shares will be allotted and issued by the Company at HK\$59.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per H Share under the Global Offering. Approvals for the listing of and permission to deal in the Over-allotment Shares have already been granted by the Listing Committee of the Stock Exchange.

The shareholding structure of the Company immediately before and immediately after the completion of the allotment and issue of the Over-allotment Shares by the Company is as follows:

Shareholder	Class	IMMEDIATELY BEFORE THE ALLOTMENT AND ISSUE OF THE OVER-ALLOTMENT SHARES		IMMEDIATELY AFTER THE ALLOTMENT AND ISSUE OF THE OVER-ALLOTMENT SHARES	
		Number of Shares	Approximate percentage of the Company's issued share capital (%)	Number of Shares	Approximate percentage of the Company's issued share capital (%)
Jiang Wei	Domestic Shares	46,800,000	29.25	46,800,000	29.24
You Jie	Domestic Shares	28,800,000	18.00	28,800,000	17.99
Lou Guoliang	Domestic Shares	10,000,000	6.25	10,000,000	6.25
Other 19 holders of Domestic Shares <sup>(1)</sup>	Domestic Shares	34,400,000	21.50	34,400,000	21.49
Holder of H Shares	H Shares	<u>40,000,000</u>	<u>25.00</u>	<u>40,045,300</u>	<u>25.02</u>
<b>Total</b>		<u>160,000,000</u>	<u>100.00</u>	<u>160,045,300</u>	<u>100.00</u>

*Note:*

- (1) Each of the other 19 holders of Domestic Shares does not hold more than 5% of our total share capital after the Global Offering.

The additional net proceeds of approximately HK\$2.62 million, after deducting the underwriting commissions, transaction levy and trading fee, from the exercise of the Over-allotment Option will be used by the Company for the purposes as set out in the section headed “Future Plans and Use of Proceeds — Use of Proceeds” in the Prospectus.

## STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on 23 May 2015, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offer.

The Company was informed by UBS AG Hong Kong Branch, the Stabilizing Manager, that the stabilizing actions undertaken by UBS AG Hong Kong Branch, its affiliates or any person acting for it during the stabilization period were:

- (i) over-allocation of an aggregate of 6,000,000 additional H Shares in the International Placing, representing in aggregate of 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option; and

- (ii) successive purchases of an aggregate of 5,954,700 H Shares in the price range of HK\$53.50 to HK\$59.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period. The last purchase made by the Stabilizing Manager on the market during the course of the stabilization period was on 22 May 2015 at the price of HK\$59.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%); and
- (iii) the partial exercise of the Over-allotment Option by the Sole Global Coordinator, on behalf of the International Underwriters, on 23 May 2015 in respect of an aggregate of 45,300 H Shares, representing in aggregate of 0.11% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per H Share.

The Company continues to comply with the public float requirements under Rules 8.08(1)(a) and (b) of the Listing Rules that (a) at least 25% of the Company's total issued share capital must at all times be held by the public, and (b) the total number of issued H Shares is at least 15% of the Company's total issued share capital, with a market capitalisation of not less than HK\$50 million.

This announcement is made pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.**  
**Hou Yongtai**  
*Chairman*

Hong Kong, 25 May 2015

*As at the date of this announcement, the executive Directors of the Company are Hou Yongtai, Wu Jianying, Ling Xihua, Huang Ping and Chen Yiyi; the non-executive Directors of the Company are You Jie and Gan Renbao; and the independent non-executive Directors of the Company are Chen Huabin, Shen Hongbo, Li Yuanxu, Zhu Qin and Wong Kwan Kit.*

*\* for identification purpose only*